Prospective Research in Infants With Mild Encephalopathy

Status Completed

Clinical Trial Summary

A multicenter observational pilot study will be conducted to determine the natural history of infants with early diagnosis (≤ 6 hrs of age) of mild neonatal encephalopathy (NE) who are not qualified for therapeutic hypothermia. The intervention includes: neurologic examination by using modified Sarnat score at ≤ 6 hrs of age, 24 hrs and before discharge home, amplitude-integrated electroencephalography (aEEG) at 6 ± 3 hrs of age, brain MRI at before discharge home to 30 days of age and follow-up at 18-22 months of age. Primary outcome is the percentage of mild NE infants with evidence of brain injury defined by the presence of at least 1 abnormality of brain MRI, aEEG or neurologic examination in the neonatal period. Secondary outcome is the percentage of brain MRI, aEEG and neurological exam abnormalities, seizure, length of hospital stay, need of gavage feeds or gastrostomy at discharge home, death and long-term outcome.

Clinical Trial Description

Globally, an estimated 1.8 to 7.7 infants per 1000 live term births suffer from perinatal asphyxia, which remains an important cause of neonatal encephalopathy (NE) and neurodevelopmental impairment. Over the last six years, several randomized control trials have demonstrated that prolonged and moderate therapeutic hypothermia (TH) reduces the rate of death or disability at 18 months of age among infants who survived. In these trials, infants were eligible if there was evidence of perinatal hypoxia-ischemia and a moderate or severe degree of encephalopathy on neurological evaluation performed at ≤ 6 hrs of age. However, it has been recognized that the level of NE may change over time. Preliminary and unpublished observations from our group indicated that some infants who were not classified as moderate or severe NE had neurological abnormalities at discharge or evidence of brain injury on MRI performed during the neonatal period. Unfortunately, precise data on the outcomes of this specific population is not clear. Since TH is not offered to this population, the outcomes of infants that do not qualify for TH based on neurological evaluation performed ≤ 6 hrs of life requires a more precise investigation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01747863
Study type	Observational
Source	McGill University Health Center
Contact
Status	Completed
Phase	N/A
Start date	December 2012
Completion date	June 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02710123` - Sub-Threshold Exercise Treatment for Adolescents With Sports Related Concussion	N/A
Recruiting	`NCT02777060` - Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures	N/A
Completed	`NCT02262286` - MIND (Management of Traumatic Brain Injury Diagnosis)	N/A
Completed	`NCT01461902` - Vasospasm in Pediatric Traumatic Brain Injury	N/A
Recruiting	`NCT01198964` - Optimization of Human Cortical Stimulation
Active, not recruiting	`NCT01207050` - Effect of Rozerem on Sleep Among People With Traumatic Brain Injury	Phase 4
Completed	`NCT01201863` - Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy	Phase 4
Completed	`NCT00875329` - Traumatic Brain Injury (TBI) Screening Instruments	N/A
Completed	`NCT01035606` - Training in Goal-directed Attention Regulation for Individuals With Brain Injury	N/A
Completed	`NCT01059890` - Cerebral Antibiotics Distribution After Acute Brain Injury	Phase 1
Completed	`NCT00596765` - Neuropsychological Cognitive Behavioral Therapy for Patients With Acquired Brain Injury	N/A
Completed	`NCT00571623` - Automated Chest Physiotherapy to Improve Outcomes in Neuro	N/A
Completed	`NCT00336466` - The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS)	Phase 2
Recruiting	`NCT05105763` - Biofeedback Gait Retraining for Stiff Knee Gait Correction	N/A
Recruiting	`NCT02495558` - Cough Assessment in Patients With Severe Acquired Brain Injury	N/A
Completed	`NCT02100592` - Early Verticalization in neuroICU With ERIGO: a Safety and Feasibility Study	Phase 1/Phase 2
Completed	`NCT00797680` - Duration of Hypothermia for Neuroprotection After Pediatric Cardiac Arrest	Phase 2
Completed	`NCT00018499` - Genotype Influence on Recovery After Traumatic Brain Injury	N/A
Recruiting	`NCT02567201` - Electrophysiological Evaluation of Voluntary Attention	N/A
Withdrawn	`NCT05581927` - Whole-Body Hypothermia for Neonates With Hypoxic-Ischemic Encephalopathy(HIE)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Prospective Research in Infants With Mild Encephalopathy — PRIME

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms